Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cannabidiolin the treatment of pulmonary hypertension

A technology of pulmonary arterial hypertension and cannabidiol, applied in the field of medicine, can solve the problems of incurable mortality of pulmonary arterial hypertension, lack of cure methods for pulmonary arterial hypertension, etc.

Active Publication Date: 2019-01-25
DEYI PHARMA LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although these drugs can alleviate the symptoms of PAH to a certain extent, pulmonary hypertension is still an incurable disease with a high mortality rate. The median survival time of patients under treatment is only 2.7 years. Therefore, it is particularly urgent to find new specific therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cannabidiolin the treatment of pulmonary hypertension
  • Application of cannabidiolin the treatment of pulmonary hypertension
  • Application of cannabidiolin the treatment of pulmonary hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] Example 1: Test of the influence of cannabidiol on pulmonary hypertension caused by hypoxia

[0087] 1. Experimental animals, reagents and instruments

[0088] (1) Experimental animals

[0089] 4-6 weeks old, healthy and lively, with shiny coat color, weighing (25.15±2.15) g, C57BL / 6 (Experimental Animal Center of Military Science and Medical College, SPF grade). Divided into four groups:

[0090] Group 1 (normoxic wild type, as a control group): under normoxia, 10 female mice and 10 male mice;

[0091] Group 2 (anoxic wild type, as a control group): under hypoxic conditions, 10 female mice and 10 male mice;

[0092] Group 3 (10mg / kg, experimental group): gavage treatment under hypoxic conditions, 10 female mice and 10 male mice at 10mg / kg;

[0093] Group 4 (50 mg / kg, experimental group): intragastric administration under hypoxic conditions, 10 female mice and 10 male mice at 50 mg / kg.

[0094] (2) Administration method

[0095] The mice in groups 2-4 were place...

Embodiment 2

[0152] Example 2: In vitro experiment of cannabidiol treatment of LPS-induced macrophages

[0153] 1. Experimental animals, reagents and instruments

[0154] 2-month-old C57BL / 6 mice (Experimental Animal Center, Military Science Medical College, SPF grade)

[0155] RPMI-1640 (Sigma)

[0156] Cannabidiol (CBD, Yunnan Hansu Biotechnology Co., Ltd.)

[0157] LPS (Sigma)

[0158] Fluorescent quantitative PCR instrument (Roche)

[0159] 2. Experimental method

[0160] Primary alveolar macrophages were isolated according to the method of Yang et al. (Yang, H.M., Ma, J.Y., Castranova, V., and Ma, J.K. (1997). Effects of diesel exhaust particles on the release of interleukin-1 and tumor necrosis factor- alpha from rat alveolarmacrophages. Experimental lung research 23, 269-284.): 2-month-old mice were taken, and the animals were anesthetized by intraperitoneal injection of pentobarbital. Fix the patient in a supine position, disinfect the neck, cut the skin of the neck, peel o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the medical field and relates to the application of cannabidiol (CBD) in the treatment of pulmonary hypertension. The cannabidiol can be used as a sole active ingredient or incombination with other active ingredients to prepare a drug for treating pulmonary hypertension.The present invention relates to the use of any one of (1) to (3) below for the preparation of a medicament for the treatment and / or prevention of pulmonary hypertension:(1) cannabidiol, (2) a plant extract containing cannabidiol, preferably, the plant extract is a cannabis extract, and (3) a pharmaceutical composition comprising cannabidiol and one or more pharmaceutically acceptable adjuvants. The invention finds out the effect of cannabidiol on inhibiting pulmonary hypertension through experimental research, and is especially suitable for treating pulmonary hypertension caused by hypoxemia.

Description

technical field [0001] The invention belongs to the field of medicine and relates to the application of cannabidiol in the treatment of pulmonary hypertension. Background technique [0002] Pulmonary arterial hypertension (PAH) has complex etiology and is caused by a variety of heart, lung or pulmonary vascular diseases. Pulmonary arterial hypertension is characterized by pulmonary arteriolar vascular remodeling and pulmonary artery vascular smooth muscle proliferation, manifested by increased pulmonary circulation pressure and resistance, increased right heart load, right heart dysfunction, and reduced pulmonary blood flow, resulting in a series of clinical manifestations ; During the course of the disease, pulmonary hypertension often develops progressively. In particular, right heart failure caused by enhanced pulmonary artery vascular tension is a disease that seriously threatens human life and health. [0003] Pulmonary hypertension is divided into primary and seconda...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/05A61K36/60A61K45/06A61P11/00A61P9/12A61P29/00A61K31/5585A61K31/5578A61K31/506A61K31/519A61K31/53A61K31/4985
CPCA61K31/05A61K31/4985A61K31/506A61K31/519A61K31/53A61K31/5578A61K31/5585A61K36/60A61K45/06A61K2300/00
Inventor 张可谭昕于朝晖李向东
Owner DEYI PHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com